NEOS Investment Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. $IONS

NEOS Investment Management LLC trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 56.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 12,306 shares of the company’s stock after selling 15,855 shares during the quarter. NEOS Investment Management LLC’s holdings in Ionis Pharmaceuticals were worth $805,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Steigerwald Gordon & Koch Inc. purchased a new position in Ionis Pharmaceuticals in the third quarter valued at about $25,000. Golden State Wealth Management LLC raised its position in shares of Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after purchasing an additional 250 shares in the last quarter. Mather Group LLC. purchased a new position in shares of Ionis Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Allworth Financial LP boosted its stake in shares of Ionis Pharmaceuticals by 231.8% during the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after buying an additional 517 shares during the last quarter. Finally, Meeder Asset Management Inc. grew its position in shares of Ionis Pharmaceuticals by 620.2% during the third quarter. Meeder Asset Management Inc. now owns 713 shares of the company’s stock worth $47,000 after buying an additional 614 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Wall Street Analysts Forecast Growth

IONS has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, January 22nd. Bank of America raised their price objective on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Piper Sandler upped their target price on shares of Ionis Pharmaceuticals from $77.00 to $87.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Barclays started coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, January 28th. They set an “overweight” rating and a $95.00 price target on the stock. Finally, Royal Bank Of Canada lifted their price target on Ionis Pharmaceuticals from $82.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.95.

Ionis Pharmaceuticals Trading Up 0.0%

Ionis Pharmaceuticals stock opened at $83.15 on Friday. Ionis Pharmaceuticals, Inc. has a 1 year low of $23.95 and a 1 year high of $86.74. The firm’s 50-day moving average is $80.93 and its 200-day moving average is $70.67. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.78 and a current ratio of 2.79. The company has a market cap of $13.47 billion, a P/E ratio of -49.20 and a beta of 0.29.

Insider Transactions at Ionis Pharmaceuticals

In other news, EVP Eric Swayze sold 23,463 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $79.12, for a total transaction of $1,856,392.56. Following the completion of the transaction, the executive vice president directly owned 30,453 shares of the company’s stock, valued at approximately $2,409,441.36. This represents a 43.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joseph H. Wender sold 28,000 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $80.82, for a total value of $2,262,960.00. Following the sale, the director owned 36,035 shares in the company, valued at $2,912,348.70. The trade was a 43.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 481,356 shares of company stock valued at $38,987,621 over the last ninety days. Insiders own 2.60% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.